Evidence map›Paper›PMID 27573034›Full record

Trial reportCirculation2016

Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure).

Mark C Petrie, Pardeep S Jhund, Lilin She, Christopher Adlbrecht, Torsten Doenst, Julio A Panza, James A Hill, Kerry L Lee, Jean L Rouleau, David L Prior and 10 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00023595 (Surgical Treatment for Ischemic Heart Failure), which is not on this map. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00023595 phase3completednot on this map

Surgical Treatment for Ischemic Heart Failure (STICH)

TypeinterventionalSponsorDuke UniversityRan2002 to 2015Enrolled2,136ConditionsCardiovascular Diseases, Coronary Disease, Heart Failure, Congestive, Heart DiseasesArmsCABG surgery plus MED, Active Medication Alone, CABG plus MED and SVR
3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it, 168 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Percutaneous Coronary Intervention for Heart Failure: Worth the Cost?Circulation. Cardiovascular quality and outcomes · 2024
    Article
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 3 countries.

Mark C Petrie *BHF GCRC, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
Pardeep S Jhund *BHF GCRC, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
Lilin SheDuke Clinical Research Institute and Departments of Biostatistics and Bioinformatics (KLL) and Medicine (EJV), Duke University School of Medicine, Durham, North Carolina, USA.
Christopher AdlbrechtDepartment of Medicine II, Division of Cardiology, Medical University of Vienna and 4 Medical Department, Hietzing Hospital, Vienna, Austria.
Torsten DoenstDepartment of Cardiothoracic Surgery, University Hospital Jena, Friedrich-Schiller University of Jena, Germany.
Julio A PanzaWestchester Medical Center and New York Medical College, Valhalla, New York, USA.
James A HillUniversity of Florida, Gainesville, USA.
Kerry L LeeDuke Clinical Research Institute and Departments of Biostatistics and Bioinformatics (KLL) and Medicine (EJV), Duke University School of Medicine, Durham, North Carolina, USA.
Jean L RouleauUniversity of Montreal, Montreal Heart Institute, Montreal, Canada.
David L PriorDepartment of Cardiology, St. Vincent's Hospital, University of Melbourne, Australia.
Imtiaz S AliLibin Cardiovascular Institute of Alberta, University of Calgary, Canada.
Jyotsna MadduryDepartment of Cardiology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, India.
Krzysztof S GolbaDepartment of Electrocardiology and Heart Failure, Medical University of Silesia, Katowice, Poland.
Harvey D WhiteAuckland City Hospital Greenlane Cardiovascular Services, Auckland, New Zealand.
Peter CarsonWashington, DC VA Medical Center, USA.
Lukasz ChrzanowskiDepartment of Cardiology, Medical University of Lodz, Poland.
Alexander RomanovArrhythmia Department and Electrophysiology Laboratory, State Research Institute of Circulation Pathology, Novosibirsk, Russia.
Alan B MillerDepartment of Cardiology, University of Florida, Jacksonville, USA.
Eric J VelazquezDuke Clinical Research Institute and Departments of Biostatistics and Bioinformatics (KLL) and Medicine (EJV), Duke University School of Medicine, Durham, North Carolina, USA.
STICH Trial Investigators
Friedrich Schiller University Jena · DEUniversity of Calgary · CAUniversity of Glasgow · GB

Funding

STICH Trial-Coordinating CenterU01HL069015 · NHLBI · DUKE UNIVERSITY · PI JONES, ROBERT H · 2002 to 2011
$27.3M
STICHESR01HL105853 · NHLBI · DUKE UNIVERSITY · PI AL-KHALIDI, HUSSEIN · 2011 to 2015
$10.2M
STICH Trial-Statistical and Data Coordinatiing CenterU01HL069013 · NHLBI · DUKE UNIVERSITY · PI LEE, KERRY L · 2002 to 2010
$5.0M
NHLBI NIH HHS R01 HL105853NHLBI NIH HHS U01 HL069013NHLBI NIH HHS U01 HL069015
6 · The paper itself

Abstract

backgroundAdvancing age is associated with a greater prevalence of coronary artery disease in heart failure with reduced ejection fraction and with a higher risk of complications after coronary artery bypass grafting (CABG). Whether the efficacy of CABG compared with medical therapy (MED) in patients with heart failure caused by ischemic cardiomyopathy is the same in patients of different ages is unknown.

methodsA total of 1212 patients (median follow-up, 9.8 years) with ejection fraction ≤35% and coronary disease amenable to CABG were randomized to CABG or MED in the STICH trial (Surgical Treatment for Ischemic Heart Failure).

resultsMean age at trial entry was 60 years; 12% were women; 36% were nonwhite; and the baseline ejection fraction was 28%. For the present analyses, patients were categorized by age quartiles: quartile 1, ≤54 years; quartile, 2 >54 and ≤60 years; quartile 3, >60 and ≤67 years; and quartile 4, >67 years. Older versus younger patients had more comorbidities. All-cause mortality was higher in older compared with younger patients assigned to MED (79% versus 60% for quartiles 4 and 1, respectively; log-rank P=0.005) and CABG (68% versus 48% for quartiles 4 and 1, respectively; log-rank P<0.001). In contrast, cardiovascular mortality was not statistically significantly different across the spectrum of age in the MED group (53% versus 49% for quartiles 4 and 1, respectively; log-rank P=0.388) or CABG group (39% versus 35% for quartiles 4 and 1, respectively; log-rank P=0.103). Cardiovascular deaths accounted for a greater proportion of deaths in the youngest versus oldest quartile (79% versus 62%). The effect of CABG versus MED on all-cause mortality tended to diminish with increasing age (P

conclusionsCABG added to MED has a more substantial benefit on all-cause mortality and the combination of all-cause mortality and cardiovascular hospitalization in younger compared with older patients. CABG added to MED has a consistent beneficial effect on cardiovascular mortality regardless of age. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00023595.

Indexed as

Coronary Artery BypassHeart FailureMyocardial IschemiaStroke VolumeVentricular Dysfunction, LeftAgedAge FactorsDisease-Free SurvivalFemaleFollow-Up StudiesHumansMaleMiddle AgedSurvival Rateagingcoronary artery bypasscoronary artery diseaseheart failure

Identifiers

PMID27573034
PMCPMC5089908
OpenAlexW2515445066

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.